文献速递外周动脉疾病

BASIL试验与英国当代系列股腘动脉普通球囊血管成形术治疗慢性肢体威胁性缺血的比较

Comparison of femoropopliteal plain balloon angioplasty for chronic limb-threatening ischemia in the BASIL trial and in a UK contemporary series.
PubMed 文献 · J Vasc Surg · 2021-07-21

该研究比较了2009-2014年当代系列(CS)与1999-2004年BASIL-1试验中股腘动脉普通球囊血管成形术(FP-PBA)±裸金属支架(BMS)治疗慢性肢体威胁性缺血(CLTI)的临床结局。

要点

  • 当代系列中FP-PBA±BMS治疗的CLTI患者无截肢生存和总生存显著劣于BASIL-1试验。
  • 当代系列患者年龄更大,BMS使用更多,但即刻技术成功率无显著差异。
  • 保肢、免于再干预和免于主要不良肢体事件在两组间无显著差异。

核心结论

  • 当代系列(2009-2014)接受FP-PBA±BMS优先血运重建策略的CLTI患者,其无截肢生存和总生存显著劣于10年前BASIL-1试验(1999-2004)中接受相同策略的患者。

研究设计与样本

  • 研究比较了当代系列(CS,2009-2014年,n=237)与BASIL-1试验(B1,1999-2004年,n=218)中接受股腘动脉普通球囊血管成形术(FP-PBA)±选择性裸金属支架(BMS)的慢性肢体威胁性缺血患者。
  • 基线及临床结局数据来自前瞻性收集的医院数据和B1试验病例报告表。

主要发现

  • B1患者更可能为当前吸烟者,较少接受最佳药物治疗,并接受了更广泛的血管内干预。

临床怎么用

  • 对于CLTI患者,采用FP-PBA±BMS优先的血运重建策略时,需注意当代实践中患者年龄更大、合并症更多可能影响生存结局。
  • 与历史试验相比,当代CLTI患者接受FP-PBA±BMS后的无截肢生存和总生存可能更差,临床决策时应综合评估患者基线特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since the turn of the millennium, there has been a worldwide trend towards an endovascular-first strategy where possible revascularization strategy for chronic limb-threatening ischemia. There is concern that this may be inappropriate and can result in net patient harm. The aim of this study, therefore, is to compare important clinical outcomes following femoropopliteal plain balloon angioplasty (FP-PBA), with selective use of bare metal stents (BMSs), in a contemporary series (CS) of patients treated in our unit between 2009 and 2014 with those observed following FP-PBA ± BMS in the United Kingdom National Institute of Health Research Health Technology Assessment-funded Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL-1 [B1]) trial (treated 1999-2004). METHODS: Baseline and clinical outcome data (amputation-free survival [AFS], overall survival [OS], limb salvage, freedom from reintervention, and freedom from major adverse limb events) were obtained from prospectively gathered hospital data and B1 trial case record forms. RESULTS: There were 237 CS and 218 B1 patients. CS patients were older (77 vs 73 years; P = .0002). B1 patients were more likely to be current smokers, less likely to be on best medical therapy, and underwent more extensive endovascular interventions. CS had more hospital admissions (4 vs 2; P < .0001) before they reached their primary endpoint (AFS). Immediate technical success was nonsignificantly higher in the CS patients (87% vs 83%; P = .2). BMS were used in 20 CS (8%) and 2 B1 (1%) patients (P = .0002). AFS (hazard ratio, 0.64; 95% confidence interval, 0.49-0.82; P = .0005) and OS (hazard ratio, 0.58; 95% confidence interval, 0.44-0.76; P = .0001) were significantly worse in the CS cohort. There was no significant difference in limb salvage, freedom from reintervention, or freedom from major adverse limb events. CONCLUSIONS: Patients with chronic limb-threatening ischemia managed in our unit (2009-2014) by means of a FP-PBA ± BMS first (where possible) revascularization strategy experienced significantly worse AFS and OS than patients treated with FP-PBA ± BMS in the B1 trial 10 years earlier (1999-2004).

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Meecham L, Popplewell M, Bate G, et al. Comparison of femoropopliteal plain balloon angioplasty for chronic limb-threatening ischemia in the BASIL trial and in a UK contemporary series. J Vasc Surg. 2021. PMID: 34298121. doi:10.1016/j.jvs.2021.06.475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。